QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:VSAR

Versartis (VSAR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free VSAR Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.18
▼
$1.30
50-Day Range
$1.19
▼
$1.19
52-Week Range
$1.14
▼
$2.76
Volume
349,963 shs
Average Volume
479,436 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
VSAR stock logo

About Versartis Stock (NASDAQ:VSAR)

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

VSAR Stock News Headlines

July 21, 2023 | thestreet.com
16 Biopharma Companies Besides Medivation That Are Attractive Targets
December 28, 2022 | thestreet.com
Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 11, 2022 | finance.yahoo.com
Zluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo Finance
May 9, 2022 | seekingalpha.com
Ascendis Pharma: Biotech Bear Provides Attractive Entry Point - Seeking Alpha
March 21, 2022 | thestreet.com
Versartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & Losers
September 22, 2021 | prnewswire.com
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm - PRNewswire
September 3, 2021 | finance.yahoo.com
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary - Yahoo Finance
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
September 2, 2021 | streetinsider.com
Cidara Therapeutics (CDTX) Appoint Preetam Shah as CFO and CBO, and Shane Ward as Chief Legal Officer and Corporate Secretary - StreetInsider.com
July 22, 2021 | entrepreneur.com
3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170% - Entrepreneur
See More Headlines
Receive VSAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VSAR
CUSIP
N/A
CIK
1513818
Web
www.versartis.com
Phone
(936) 355-1910
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Gail Frances McIntyre
    President, Chief Executive Officer & Director
  • Vinay Shah
    Chief Financial Officer
  • Reshma Rangwala
    Chief Medical Officer
  • Amy Franke
    Vice President-Clinical Operations
  • Randy Anderson
    Senior Vice President-Data Sciences

Key Competitors

View All Competitors

VSAR Stock Analysis - Frequently Asked Questions

How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.69.

What other stocks do shareholders of Versartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Genocea Biosciences (GNCA), Novavax (NVAX), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

This page (NASDAQ:VSAR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes